Epizyme Inc represents values of innovation, integrity, and dedication to improving patients' lives. With a strong corporate philosophy focused on developing novel therapies for patients with cancer and other serious diseases, Epizyme strives to make a lasting impact in the field of personalized medicine. Through their cutting-edge research and development efforts, Epizyme aims to deliver transformative treatments that target the underlying causes of diseases. By prioritizing collaboration, scientific excellence, and patient-centered care, Epizyme exemplifies a commitment towards discovering breakthrough therapies and advancing the medical industry.

Epizyme Inc is primarily present in the United States and has a strong market presence in this region. As a biopharmaceutical company, Epizyme focuses on discovering and developing novel cancer treatments. Headquartered in Cambridge, Massachusetts, Epizyme has strategically positioned itself in one of the leading biotech clusters in the world. With a robust pipeline of innovative therapies, Epizyme aims to address unmet needs in patients with genetically-driven cancers. As a prominent player in the U.S. biotech industry, Epizyme Inc has established itself as a key contributor to the advancement of precision medicine.

Epizyme Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include obtaining the accelerated approval of TAZVERIK™ (tazemetostat) by the U.S. FDA for the treatment of certain patients with epithelioid sarcoma. The company has also received the initial approval for tazemetostat in follicular lymphoma patients with EZH2 mutations. Additionally, Epizyme Inc has successfully completed clinical trials, demonstrating positive results in various indications, and has entered into collaborations with renowned pharmaceutical companies for the development and commercialization of potential therapeutic candidates. These milestones highlight Epizyme Inc's dedication to advancing innovative treatments in the field of oncology.

Epizyme Inc is a renowned biopharmaceutical company that focuses on developing personalized therapeutics for patients with genetically-driven diseases. Established in 2007, Epizyme has built a strong foundation of expertise in the field of epigenetics, studying how genes are regulated and exploring novel treatment avenues. The company's proprietary capabilities enable them to discover and develop potential breakthrough therapies, primarily targeting cancers and rare diseases. Epizyme's dedication to innovation and collaboration has resulted in various partnerships with leading pharmaceutical companies. With its dedicated team, Epizyme continues to strive towards improving patients' lives by advancing cutting-edge treatments based on the understanding of epigenetic modifications and their role in disease progression.

The main competitors of Epizyme Inc in the market include companies like Merck & Co., Inc., GlaxoSmithKline plc, and Celgene Corporation.

Epizyme Inc is primarily active in the pharmaceutical and biotechnology industries.

Epizyme Inc is a biopharmaceutical company with a unique business model focused on discovering, developing, and commercializing personalized medicines for patients with genetically defined cancers. They leverage their proprietary epigenetic drug discovery platform to identify novel therapeutics targeting specific enzymes involved in regulating gene expression. By targeting these enzymes, Epizyme aims to address the underlying genetic driver of cancer and provide targeted therapies that could potentially offer improved outcomes for patients. The company's business model revolves around research, development, clinical trials, and partnerships to bring innovative treatments to the market for patients in need.

De Epizyme K/W is -0,92.

De Epizyme KUV is 1,20.

De AlleAktien Kwaliteitsscore voor Epizyme is 7/10.

De verwachte Epizyme omzet is 126,19 mln. USD.

De verwachte Epizyme winst is -163,37 mln. USD.

Epizyme Inc is a US-based biopharmaceutical company focused on the discovery and development of therapies for the treatment of cancer and genetic diseases. The company specializes in developing drugs that target a new class of enzymes called Histone Deacetylases (HDACs), which are crucial for regulating gene expression and play a significant role in cancer initiation and the progression of genetic diseases. Epizyme operates its business in three main segments: Research & Development: Research and development is the core of Epizyme's business. The company has built an extensive research and development infrastructure to develop new drugs against cancer and genetic diseases. The research is based on identifying new HDAC inhibitors that inhibit the activity of HDAC enzymes and thus regulate gene expression. Epigenetic Diagnostics: Epizyme has developed a diagnostic platform called EpisonaTM based on DNA methylation. This technology is used for early detection of cancer and personalized medicine. EpisonaTM is being developed by Epizyme in collaboration with leading academic institutions and companies to diagnose and predict cancer types such as leukemia, lymphoma, and lung cancer. Product Marketing: Epizyme offers a wide range of products based on HDAC inhibitors for the treatment of cancer and genetic diseases. The company has conducted various clinical studies to prove the effectiveness of its drugs. Epizyme has the potential to become a global leader in the HDAC inhibitor industry. Recently, Epizyme launched a drug called Tazemetostat. It is an oral inhibitor of histone deacetylases approved for the treatment of patients with certain types of non-Hodgkin lymphomas and soft tissue sarcomas. Tazemetostat has been approved by the US Food and Drug Administration (FDA) and is the first drug developed by Epizyme to enter the market. Epizyme has partnerships with other companies to advance its research and product development. One important partnership is with Celgene Corporation, a leading company in cancer research. The collaboration includes co-development of new HDAC inhibitors and maintaining joint patent and licensing agreements. Overall, Epizyme's business model is specialized in developing HDAC inhibitors to treat cancer and genetic diseases. The company will continue to invest in research and development to strengthen its position as a leader in the HDAC inhibitor industry. Epizyme also relies on broad partnerships to advance its research and product development and bring innovative products for the treatment of cancer and genetic diseases to the market.

Epizyme keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Epizyme of het bedrijf keert geen dividend uit.

De ISIN van Epizyme is US29428V1044.

Het WKN van Epizyme is A1T9L2.

De ticker van Epizyme is EPZM.

Binnen de laatste 12 maanden betaalde Epizyme een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Epizyme naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Epizyme is momenteel .

Epizyme betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Epizyme betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Epizyme wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Epizyme van 2-10-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 2-10-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 2-10-2024.

In het jaar 2023 heeft Epizyme 0 USD aan dividenden uitgekeerd.

De dividenden van Epizyme worden in USD uitgekeerd.